Nasal administration of Protollin enhances monocyte phagocytosis and decreases CD8⁺ T cell cytotoxicity in subjects with early Alzheimer's disease: a Phase 1 clinical trial.

Panayota Kolypetri; Patrick da Silva; Ronaldo S Francisco; Dan Frenkel; Rachael R Cecere; Pien C.J. Kiliaan; Federico Montini; Shrishti Saxena; William A. Clementi; Xuejun Liu; Cheng Sun; Regan W. Bergmark; Tarun Singhal; Taylor J. Saraceno; Joseph Zimmermann; Seth A. Gale; Dennis J Selkoe; Tanuja Chitnis; H L Weiner

doi:10.1038/s41514-026-00397-3

Key Points

The aim is to evaluate the effects of nasal Protollin on immune response in early Alzheimer's disease.
Phase 1 clinical trial
Weekly administration of 1.0 mg nasal Protollin for 6 months
ClinicalTrials.gov registration no NCT07187141.
Nasal administration of Protollin increases monocyte phagocytosis
Decreased CD8+ T cell cytotoxicity observed
Results suggest potential for further investigation in Phase 2 trials.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase 1 trial finds nasal Protollin modulates immunity and shows promise for Alzheimer's, indicating future studies.

Abstract

T cell activation and cytotoxicity. Our results provide the basis for a phase 2 study of nasal Protollin in subjects with AD in which nasal Protollin at a dose of 1.0 mg will be administered weekly over 6 months to modulate peripheral immunity and clear amyloid from the brain. ClinicalTrials.gov registration no NCT07187141.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kolypetri et al. (2026) studied this question.

synapsesocial.com/papers/6a265becad53cfb9357c53cd https://doi.org/10.1038/s41514-026-00397-3

View Full Paper

Ask AI

Bookmark

Share

Nasal administration of Protollin enhances monocyte phagocytosis and decreases CD8⁺ T cell cytotoxicity in subjects with early Alzheimer's disease: a Phase 1 clinical trial.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Nasal administration of Protollin enhances monocyte phagocytosis and decreases CD8⁺ T cell cytotoxicity in subjects with early Alzheimer's disease: a Phase 1 clinical trial.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading